Skip to content

KLHL1 suppresses triple-negative breast cancer progression by promoting M1 macrophage polarization via APOC2 degradation.

Aug 2026 · Biochimica et Biophysica Acta - Molecular Basis of Disease · Vol 1873, pp. 168408 · 0 citations · 52 references
Medicine

TL;DR

Findings reveal that activation of the KLHL1/APOC2 axis enhances M1 macrophage polarization and inhibits TNBC progression, providing novel insights into the immune regulatory mechanisms underlying TNBC development.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by an immunosuppressive tumor microenvironment and resistance to chemotherapy. Previous studies have indicated that apolipoprotein C-II (APOC2) is involved in the immune microenvironment of several malignancies and is upregulated in breast cancer; however, the molecular mechanisms through which APOC2 regulates the immune microenvironment in TNBC remain poorly understood. In the present study, we found that APOC2 was upregulated in TNBC tissues and was negatively correlated with M1 macrophage infiltration. APOC2 overexpression in 4 T1 cells promoted tumor progression by enhancing cell proliferation, migration, and invasion, while suppressing M1 macrophage polarization. In addition, KLHL1, a substrate adaptor for the Cullin3-RING E3 ubiquitin ligase complex, was found to interact with APOC2, and KLHL1 overexpression reversed the biological effects induced by APOC2. Mechanistically, KLHL1 promoted APOC2 protein degradation through the ubiquitin-proteasome pathway, thereby enhancing M1 macrophage polarization and suppressing the malignant behavior of tumor cells. Finally, in vivo xenograft experiments demonstrated that APOC2 reduced M1 macrophage polarization and increased tumor weight and volume, whereas KLHL1 overexpression counteracted the oncogenic effects of APOC2. Collectively, these findings reveal that activation of the KLHL1/APOC2 axis enhances M1 macrophage polarization and inhibits TNBC progression, providing novel insights into the immune regulatory mechanisms underlying TNBC development.

View source

Similar papers

Open access Sep 2026

Breast cancer-associated fibroblast-derived exosomal miR-1290 promotes triple-negative breast cancer cell proliferation

It is demonstrated that treatment with the mTOR inhibitor rapamycin and the FDA-approved rapamycin analog everolimus effectively suppressed miR-1290-induced TNBC cell proliferation, suggesting a potential therapeutic strategy for TNBC.

Jinkwon Lee, Taesang Son, Gyeonghwa Kim et al. · 0 citations
Sep 2026

METTL3 Promotes the Growth of Triple-Negative Breast Cancer Cells by Modulating Ferroptosis-Related Oxidative Stress via the ELF1/GPX4 Axis.

A novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers is suggested, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.

Jin-Chen Wang, Wei Wang, Jun-Jie Hu et al. · 0 citations
Open access Sep 2026

ZBTB1 Regulates Glycolysis and Chemotherapy Resistance Through Interacting with c-Myc in Triple Negative Breast Cancer

Background/Objectives: Our previous study identified ZBTB1 as a novel tumor suppressor in estrogen receptor-positive (ER+) breast cancer. Moreover, The Cancer Genome Atlas (TCGA) data analysis showed a much lower level of ZBTB1 in triple-negative breast cancer than in ER+ breast cancer. Triple negative breast cancer (T...

Na Qian, Song-Yao Sun, Cong Ouyang et al. · 0 citations
Open access Sep 2026

MXRA5 promotes the progression and metastasis of breast cancer via activation of the epithelial-to-mesenchymal transition pathway

Elevated MXRA5 expression exhibited a positive correlation with advanced lymph node metastasis and impaired clinical prognosis, and its potential as a valuable prognostic biomarker and therapeutic target for managing metastatic disease is revealed.

Jian Wang, Jie Tang, Yaoxin Wang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.